# CheckMate057 (NCT01673867)

> Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: previously treated metastatic non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01673867
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Squamous Cell Non-small Cell Lung Cancer
- Interventions: Nivolumab; Docetaxel
- Enrollment: 582
- Primary outcome: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint

## Indexed commentary on CheckMate057 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 4
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=checkmate057-nct01673867

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01673867", "email": "<work email>"}; the inbox owner confirms by the emailed link.